Therapeutic compositions and methods for treating viral infection
AssigneeMyriad Genetics, Inc.
InventorsScott Morham, Kenton Zavitz, Adrian Hobden
Life of this patent
Estimating the term…
Abstract
Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof.
Claims59
A composition comprising a peptide associated with a transporter that is capable of increasing the uptake of said peptide by a mammalian cell,
- wherein said peptide includes an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
A composition comprising a hybrid polypeptide, said hybrid polypeptide consists of a peptide covalently linked to a peptidic transporter that is capable of increasing the uptake of said peptide by a mammalian cell by at least 100%,
- wherein said hybrid polypeptide consists of from about 8 to about 100 amino acid residues, and wherein said peptide comprises an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
A composition comprising a hybrid polypeptide, said hybrid polypeptide consists of a peptide covalently linked to a peptidic transporter that is capable of increasing the uptake of said peptide by a mammalian cell by at least 200%,
- wherein said hybrid polypeptide consists of from about 10 to about 30 amino acid residues, and wherein said peptide comprises an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
An isolated peptide consisting of a contiguous amino acid sequence of from 7 to about 30 amino acid residues of a viral protein selected from the group consisting of HCV polyprotein, HSV UL42 protein, variola virus A10L protein, vaccinia virus virion core protein P4a, and human parainfluenza virus hemagglutinin-neuramimidase, wherein said contiguous amino acid sequence encompasses the YPXL motif of said viral protein, and wherein said peptide is capable of binding a region including the amino acid residues 121 to 435 of AP-50.
A method for treating an infection caused by a virus selected from the group consisting of HCV, HSV1 and variola virus, said method comprising:
- introducing into a patient in need of such treatment a peptide consisting of from 8 to about 30 amino acid residues and having an amino acid sequence motif YPXL, wherein X is an amino acid, and wherein said peptide is capable of binding a region including the amino acid residues 121 to 435 of AP-50.
A method for treating an infection caused by a virus selected from the group consisting of HCV, HSV1 and variola virus, said method comprising:
- administering to a patient in need of such treatment a composition comprising a peptide associated with a transporter that is capable of increasing the uptake of said peptide by a mammalian cell,
- wherein said peptide includes an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
A method for treating an infection caused by a virus selected from the group consisting of HCV, HSV1 and variola virus, said method comprising:
- administering to a patient in need of such treatment a hybrid polypeptide, said hybrid polypeptide consists of a peptide covalently linked to a peptidic transporter that is capable of increasing the uptake of said peptide by a mammalian cell by at least 100%,
- wherein said hybrid polypeptide consists of from about 8 to about 100 amino acid residues, and wherein said peptide comprises an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
A method for treating an infection caused by a virus selected from the group consisting of HCV, HSV1 and variola virus, said method comprising:
- administering to a patient in need of such treatment a composition comprising a hybrid polypeptide, said hybrid polypeptide consists of a peptide covalently linked to a peptidic transporter that is capable of increasing the uptake of said peptide by a mammalian cell by at least 200%,
- wherein said hybrid polypeptide consists of from about 10 to about 30 amino acid residues, and wherein said peptide comprises an amino acid sequence motif YPXL and is capable of binding a region including the amino acid residues 121 to 435 of AP-50, wherein X is an amino acid.
Dependencies are inferred from the claim text.